10-Q/A: GT Biopharma Restates Q2 2025, Cites Material Errors

GT Biopharma, Inc. has filed an amended quarterly report for Q2 2025, restating financials due to material errors in classifying Greenshoe Rights as a liability, significantly increasing net loss and accumulated deficit.

Summary

• GT Biopharma, Inc. (GTBP) filed a Form 10-Q/A to amend and restate its Quarterly Report for the fiscal quarter ended June 30, 2025, to correct material errors.
• The restatement resulted from the reevaluation of Greenshoe Rights connected to Series L Convertible Preferred Stock, which were incorrectly classified as equity and should have been a liability, requiring mark-to-market accounting.
• The correction led to a significant increase in the Greenshoe Rights liability by $28,736,000 and a corresponding increase in the accumulated deficit.
• Net loss for the three months ended June 30, 2025, increased from $(1,433,000) to $(30,169,000) and for the six months, from $(2,209,000) to $(30,945,000).
• Net loss per share for the three months ended June 30, 2025, increased from $(0.55) to $(10.92) and for the six months, from $(0.90) to $(12.12).
• The restatement did not impact total net cash provided by or used in operating, investing, or financing activities.
• The company's disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to these errors, constituting a material weakness in internal control over financial reporting.
• Management has adopted additional internal controls, including engaging accounting consultants for complex financial transactions, to remediate the material weakness.
• The company continues to operate as a clinical-stage biopharmaceutical company focused on TriKE and Dual Targeting TriKE platforms for immuno-oncology products.
• Substantial doubt exists about the company's ability to continue as a going concern within one year due to sustained operating losses and insufficient cash resources without additional financing.
• GT Biopharma regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 13, 2025, after submitting a compliance plan.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the material restatement of financials, significant increase in net loss, identified material weakness in internal controls, and the explicit 'going concern' warning, overshadowing any operational progress.

Positives

• Net cash used in operating activities decreased to $5,216,000 for the six months ended June 30, 2025, from $7,699,000 in the prior year period.
• Net cash provided by financing activities increased to $6,493,000 for the six months ended June 30, 2025, from $2,976,000 in the prior year period, indicating successful capital raises.
• Working capital improved from a deficit of $(1,670,000) as of December 31, 2024, to a positive $4,817,000 as of June 30, 2025.
• The company successfully regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 13, 2025.
• Study enrollment for the next-generation GTB-3650 camelid nanobody product for relapsed/refractory AML and high-risk MDS began in early 2025, following FDA IND clearance in late June 2024.
• Preclinical work for GTB-5550, a B7-H3 targeted TriKE for advanced solid tumors, is advancing, with GMP manufacturing initiated and IND submission anticipated in Q4 2025.
• Research and development expenses decreased by $1.099 million for the six months ended June 30, 2025, compared to the same prior year period, primarily due to reduced production and scientific research costs.
• Selling, general, and administrative expenses decreased by $2.238 million for the six months ended June 30, 2025, compared to the same prior year period, mainly due to reduced legal fees and other cost reduction measures.

Negatives

• The company reported a significantly increased net loss of $(30,945,000) for the six months ended June 30, 2025, compared to $(5,976,000) for the same period in 2024, primarily due to the non-cash loss on initial recognition of Greenshoe Rights liability.
• Accumulated deficit increased by $28,736,000 to $(726,257,000) as a result of the restatement.
• Total stockholders' equity (deficit) significantly worsened from $2,861,000 (originally reported) to $(25,875,000) (restated) as of June 30, 2025.
• The company's disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to material errors in financial reporting.
• A material weakness in internal control over financial reporting was identified concerning the accounting for complex financial transactions (ASC 480).
• Substantial doubt exists about the company's ability to continue as a going concern within one year, necessitating additional financing.
• Interest income decreased by $177,000 for the six months ended June 30, 2025, compared to the prior year, due to lower money market fund and short-term investment balances.
• The company faces multiple legal proceedings, including disputes with a former CFO and claims related to convertible notes, which could result in significant damages or legal costs.

Risks

• The company has sustained operating losses since inception and expects them to continue, raising substantial doubt about its ability to continue as a going concern.
• Inability to secure additional financing on acceptable terms could force delays, reductions, or elimination of discretionary spending, adversely affecting business prospects and long-term liquidity.
• The identified material weakness in internal control over financial reporting regarding complex financial transactions could lead to future material misstatements if not fully remediated.
• Ongoing legal proceedings, including arbitration with a former CFO and multiple lawsuits regarding convertible notes, pose risks of adverse outcomes, significant damages, and legal expenses.
• Failure to maintain Nasdaq listing compliance, despite regaining it, could result in delisting, decreased liquidity, increased stock volatility, and difficulty in raising capital.
• The company's product candidates are in clinical stages, and there is no guarantee of regulatory approval or successful commercialization.
• Reliance on third parties like Cytovance Biologics and the University of Minnesota for R&D and manufacturing services introduces dependency risks.
• The Series L Convertible Preferred Stock and Warrants have full ratchet price protection and are subject to other adjustments, which could lead to significant dilution for common stockholders.

Future Outlook

The company anticipates submitting an IND application for GTB-5550 in the fourth quarter of 2025. It expects continued operating losses into the foreseeable future and believes existing cash resources will not be sufficient to fund anticipated operations for one year without additional financing. The company aims to be a leader in immuno-oncology therapies, targeting a broad range of indications, and is implementing processes to produce IND-ready moieties in a timely manner.

Management Comments

• Management determined that the Greenshoe Rights met the criteria for liability classification in accordance with ASC 480, leading to the restatement.
• Management concluded its disclosure controls and procedures as of June 30, 2025, were ineffective due to the identified errors.
• Management believes that if unable to obtain additional financing, existing cash resources will not be sufficient to fund the anticipated level of operations through one year from the date the financial statements are issued.
• The company intends to seek dismissal of the legal cases related to the TWF Global matter and the Silberfein, DiPietro, and Werthman Trust matters, believing the claims are without merit and intending to vigorously defend against them.

Industry Context

StockSavvy.ai notes that GT Biopharma operates in the highly competitive and capital-intensive immuno-oncology sector, focusing on novel TriKE and Dual Targeting TriKE platforms. While the pipeline shows promising preclinical data for GTB-3650 (AML/MDS) and GTB-5550 (solid tumors), the significant financial restatement and ongoing 'going concern' issues highlight the inherent risks and funding challenges common for clinical-stage biopharmaceutical companies. The shift to camelid nanobody technology for next-generation TriKEs like GTB-3650 and GTB-5550 represents an attempt to differentiate in a crowded field, but successful clinical translation and commercialization remain distant and uncertain. The company's reliance on collaborations with institutions like the University of Minnesota is a common strategy in early-stage drug development.

Comparison to Industry Standards

• GT Biopharma's net loss of $(30.9) million for the six months ended June 30, 2025, is substantial for a clinical-stage biopharma, reflecting high R&D costs and the non-cash impact of the Greenshoe Rights liability. This level of loss is not uncommon for companies in early clinical development, but the magnitude of the restatement highlights significant internal control deficiencies that are below industry best practices.
• The 'going concern' warning is a critical indicator of financial instability, a common challenge for pre-revenue biotechs, but one that typically warrants close scrutiny by investors. Compared to peers like Fate Therapeutics or Nkarta Therapeutics, which also focus on NK cell therapies, GT Biopharma's financial position appears more precarious given the restatement and the explicit doubt raised by management and auditors.
• The decrease in R&D expenses by 43% for the six months ended June 30, 2025, while potentially a cost-saving measure, could also signal a slowdown in development pace compared to more well-funded competitors who are aggressively investing in their pipelines.
• The ineffectiveness of disclosure controls and the material weakness in internal control over financial reporting are significant governance issues that are below the standards expected of publicly traded companies, especially those listed on Nasdaq. Remediation efforts are crucial but the occurrence itself is a red flag compared to industry peers.

Corporate Governance

Legal Proceedings

• Ohri Matter: AAA Arbitration Demand filed by the company against former CFO Manu Ohri for breach of fiduciary duties and contract. Mr. Ohri filed counterclaims. The final hearing was postponed indefinitely for mediation, with a status conference scheduled for August 19, 2025.
• TWF Global Matter: Z-One, LLC filed a new complaint on June 25, 2025, alleging the company breached a Convertible Note in the principal amount of $150,000 by failing to deliver conversion shares, seeking damages in excess of $500,000. The company intends to seek dismissal.
• Silberfein, DiPietro, and Werthman Trust Matters: Three separate summonses with notice filed on July 8-9, 2025, alleging breach of securities purchase agreements and convertible notes (each $100,000 principal) from 2021, seeking specific performance and damages. The company intends to demand complaints and then seek dismissal.

Related Party Transactions

• Cytovance Biologics, Inc. (related party, >5% common stock ownership): Accounts payable to Cytovance were $598,000 as of June 30, 2025. The company recognized $626,000 in R&D expenses and made cash payments of $364,000 to Cytovance for the six months ended June 30, 2025. Pre-funded warrants valued at $847,000 were issued to Cytovance as partial payment of accounts payable.
• University of Minnesota: The 2023 Sponsored Research Agreement was amended on June 18, 2025, extending its expiration to December 31, 2025, and increasing total payments due to approximately $1.9 million. R&D expenses of $431,000 were recorded for the six months ended June 30, 2025. Commitments for unbilled services amounted to $431,000 under this agreement and $1.9 million under the 2024 Clinical Trial Agreement.
• PDPC Advisors Inc. (related party): In June 2025, the company entered into an Advisory Agreement, agreeing to cash payments of $100,000 in six installments starting July 1, 2025, and issuing a pre-funded warrant to purchase 150,000 shares of common stock with a fair value of $537,000.

Stakeholder Impact

• Shareholders: Face significant dilution risk from warrant exercises and convertible preferred stock conversions, as well as potential negative impact on share price due to the restatement, increased losses, and 'going concern' doubt. The full ratchet price protection on warrants and preferred stock could exacerbate dilution.
• Investors: The restatement and identified material weakness in internal controls may erode investor confidence and increase perceived risk. The 'going concern' warning signals high financial risk.
• Employees: The company's financial instability and need for additional financing could impact job security or future compensation, although no specific details were provided.
• Creditors: The substantial increase in total liabilities, particularly the Greenshoe Rights liability, could alter the company's credit profile and increase perceived risk for existing and potential creditors.
• Regulatory Authorities (SEC, Nasdaq): The restatement and ineffective disclosure controls indicate non-compliance with regulatory standards, leading to increased scrutiny, though Nasdaq compliance was regained for equity requirements.

Next Steps

• Engage accounting consultants for complex financial transactions to remediate the material weakness in internal control over financial reporting.
• Continue efforts to secure additional financing to fund operations and address the 'going concern' doubt.
• Proceed with the GTB-3650 clinical trial, enrolling patients and collecting data.
• Advance GTB-5550 through preclinical studies and initiate GMP manufacturing, with an anticipated IND submission in Q4 2025.
• Explore and assess potential manufacturers for GTB-7550.
• Attend a status conference on August 19, 2025, for the Ohri Matter arbitration.
• Demand that Z-One, LLC and the plaintiffs in the Silberfein, DiPietro, and Werthman Trust matters file complaints, and then seek dismissal of these cases.
• Nasdaq will continue to monitor the company's compliance with the Minimum Stockholders Equity Requirement.

Key Dates

Recommendation

The restatement of financial statements, which dramatically increased the net loss and accumulated deficit, coupled with the explicit 'going concern' warning, signals severe financial distress and significant operational control deficiencies. The identified material weakness in internal controls further undermines confidence in the company's financial reporting. While there is ongoing clinical development, the fundamental financial and governance issues present an exceptionally high risk profile. The potential for further dilution from capital raises and the uncertainty of legal proceedings add to the negative outlook. A seasoned investor would likely view these factors as compelling reasons to exit the position.

Keywords

Biopharma, Immuno-oncology, TriKE, Dual Targeting TriKE, SEC Filing, 10-Q/A, Restatement, Financial Reporting, Greenshoe Rights, Convertible Preferred Stock, Warrant Liability, Going Concern, Internal Controls, Material Weakness, Clinical Trials, AML, MDS, Solid Tumors, Autoimmune Disorders, Capital Raise, Nasdaq Compliance, Legal Proceedings